ABSTRACT

The outcome of recent clinical trials in osteoporosis was the impetus for this volume. In these studies of two bisphosphonates, an interaction between bone mineral density (BMD) and the treatment effect was seen, such that these agents appeared to lose their effect as BMD increased. To practitioners this is counter-intuitive. Why should treatment w

chapter 2|14 pages

Epidemiology

chapter 3|15 pages

Pathophysiology of osteoporosis

chapter 4|13 pages

Risk stratification

chapter 7|16 pages

Strategies for prevention